Specifically, both NGF maturation and degradation are disrupted at preclinical AD stages as revealed in individuals with no cognitive impairment (NCI) but with high brain β-amyloid (Aβ) levels (HA-NCI). The gene discussed is NGF; the disease is Cognitive impairment.